Curriculum Vitae

DR. LEE DAI WEE

Medical Lecturer
  • Department of Oncology Clinical
    Faculty of Medicine
  • david.lee
  • 0379492423

BIOGRAPHY

Dr David Lee Dai Wee is a consultant clinical oncologist at the University of Malaya Medical Centre and lecturer at the Faculty of Medicine, University of Malaya. He received his undergraduate medical education at International Medical University (IMU), Malaysia, and subsequently Master of Clinical Oncology at the University of Malaya in 2020. Dr Lee also holds FRCR (Clinical Oncology) since 2022.

He completed a fellowship in experimental therapeutics under guidance of Dr Daniel Tan at the National Cancer Centre Singapore, involving in the conduct of more than 40 early-phase clinical trials. He is the principle investigator for various international multicenter clinical trials, focusing on early-phase studies, thoracic cancers, and head and neck cancers.

Dr Lee is the inaugural recipient of the American Society of Clinical Oncology (ASCO) Leadership Development Program - Asia Pacific award in 2021-2022. He received the ASCO International Development and Education Award (IDEA) in 2024, and IASLC Academy Award 2024. Currently Dr Lee serves in the ASCO Membership Advisory Group, IASLC Multidisciplinary Clinical Science Committee and FARO Council. 

ACADEMIC QUALIFICATION

  • Expert Training
    National Cancer Center Singapore
  • MClinOnc, (Onkologi)
    Universiti Malaya (UM)
  • MBBS, (Medicine and Surgery)
    International Medical University (Imu)

ADMINISTRATIVE DUTIES

  • Federation of Asian Organizations of Radiation Oncology (FARO) Council Member
    01 Jan 2023 - 31 Dec 2026 (International)
  • American Society of Clinical Oncology Membership Advisory Committee.
    05 Jun 2023 - 08 Jun 2026 (International)
  • IASLC Multidisciplinary Clinical Science Committee
    19 Dec 2023 - 30 Sep 2025 (International)
  • Scientific Review Committee of Phase 1 Unit at UMMC
    11 Dec 2023 - 31 Dec 2024 (University Malaya)
  • American Society of Clinical Oncology (ASCO) Trainee & Early Career Advisory Group
    05 May 2023 - 03 Jun 2024 (International)
  • University of Malaya - Master of Clinical Oncology: Part 2 Coordinator
    12 Jun 2023 - 31 Dec 2023 (Department)

MEMBERSHIPS

  • INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC), MEMBER
    2023 to 2024 (International)
  • AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR), MEMBER
    Since 2023 (International)
  • EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO), MEMBER
    2015 to 2024 (International)
  • ROYAL COLLEGE OF RADIOLOGISTS, MEMBER
    2022 to 2023 (International)
  • AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), MEMBER
    2019 to 2023 (International)

AWARD AND STEWARDSHIP

  • Annual Scientific Congress of Malaysian Oncological Society 2024 - Best Oral Presentation Award - Third Place
    Malaysian Oncological Society, 2024 (National)
  • ASCO International Development and Education Award (IDEA) 2024
    Conquer Cancer Foundation, 2024 (International)
  • IASLC Academy 2024
    International Association for the Study of Lung Cancer, 2024 (International)
  • ASCO Leadership Development Program Award (Asia Pacific)
    American Society of Clinical Oncology (ASCO), 2021 (International)

PUBLICATIONS

Article in Journal
WoS
  1. Lee, D. D. W. (2022). Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?, ANNALS OF ONCOLOGY. 33, S1606-S1606. doi:10.1016/j.annonc.2022.10.454
Scopus
  1. Lee D.D.-W., Ismail F. (2022). DOCETAXEL-INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN MALAYSIA, Journal of Health and Translational Medicine. 25(1), 1-4. doi:10.22452/jummec.vol25no1.1
  2. Lee, D. W., & Ho, G. F. (2020). Palbociclib in the treatment of recurrent ovarian cancer. Gynecologic Oncology Reports, 34. doi: 10.1016/j.gore.2020.100626
  3. Lee, D. W., Kang, I. H., & Ismail, F. (2020). Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study. Medical Journal of Malaysia, 75(4), 338-341.
Others
  1. Lee DW and Ho GF. (2018). External auditory meatus involvement in nasopharyngeal carcinoma. Journal of Radiotherapy in Practice. page 1 of 3. doi: 10.1017/S1460396918000067
  2. Lee D.W., Teoh D.C., Chong, F.L. (2016) Treatment of Heavily Pre-treated Metastatic Breast Cancer with Eribulin: First local experience in Sabah. Med J Malaysia 7 (6), 348-350.
  3. Lee D.W., Teoh D.C., Chong, F.L. (2015) A Case of Nasopharyngeal Carcinoma with Paraneoplastic Leukemoid Reaction: A Case Report. Med J Malaysia 70 (2), 110-111.
Article in Proceeding
  1. Lee DDW, Jamalludin Z, Satar NFA, Ho GF. Implementation of hippocampal sparing whole brain radiotherapy in a resource-limited setting. Journal of Clinical Oncology. 2024;42(23_suppl):31-.
  2. Aaron C. Tan, Yu Amanda Guo, Chowdhury Rafeed Rahman, Tira Jing Ying Tan, Stephanie Pei Li Saw, David Dai-Wee Lee, Justina Yick Ching Lam, Wai Meng David Tai, Sharmaine Jia Xin Tan, Matilda Ya Wen Boey Ya Wen, Christine Carolyn, Mei Xuan Yong, Pamela Shi Ying Kuan, Hanae Camille Carrie, Jia Chi Yeo, Iain Bee Huat Tan, Giuseppe Curigliano, Matthew C.H. Ng, Daniel Shao-Weng Tan, and Anders Skanderup. JCO Global Oncology 2023 9:Supplement_1, 23-23
  3. Lee, D., Tane, K., Permata, T. B. M., Su, Y.-L., Malik, M., & Stockler, M. R. (2023). Creating a cancer advocacy program in Indonesia. JCO Global Oncology, 9(Supplement_1), 105-105.
  4. Lee DW, Ismail F. A rare case of metastatic basal cell carcinoma. Adv Mod Oncol Res 2017; 3(6): 284

RESEARCH INTEREST

  • Early phase clinical trial (Oncology)
  • Thoracic oncology (Thoracic oncology)
  • Head and neck oncology (Head and neck oncology)

RESEARCH PROJECT

National
  1. 2023 - 2025, Bantuan Khas Penyelidikan (BKP Special)
    Novel Approach of Total Body Irradiation Using Volumetric Modulated Arc Therapy ( Co-Researcher)
Private
  1. 2023 - 2025, BEIGENE SINGAPORE PTE. LTD.
    PHASE 1 STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF THE ANTI OX40 AGONIST MONOCLONAL ANTIBODY BGB-A445 IN COMBINATION WITH THE ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS ( Principal Investigator(PI))
  2. 2024 - 2025, Hexal AG
    A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO COMPARE PHARMACOKINETICS OF GME751 (PROPOSED PEMBROLIZUMAB BIOSIMILAR) AND US-LICENSED AND EUAUTHORIZED KEYTRUDA IN PARTICIPANTS WITH STAGE II AND III MELANOMA REQUIRING ADJUVANT TREATMENT WITH PEMBROLIZUMAB ( Principal Investigator(PI))

PAPER PRESENTED

PLENARY SPEAKER
  1. Management Of Oligometastatic Disease In Lung Cancer, Annual Scientific Congress of the Malaysian Oncological Society (ASCOMOS) 2024, Malaysian Oncological Society (National) (11 Oct 2024 - 11 Oct 2024)
  2. Local recurrence of nasopharyngeal carcinoma: re-irradiation, immunotherapy, surgery?, ESTRO Meets Asia 2024, European Society for Radiotherapy and Oncology (International) (23 Aug 2024 - 25 Aug 2024)
  3. The Great Debate - This house believes peri-operative Chemo/IO + Surgery is preferred to the PACIFIC regimen in borderline resectable stage 3 NSCLC without driver mutation., Lung Cancer Symposium 2024, Lung Cancer Network Malaysia (LCNM) (International) (26 Apr 2024 - 28 Apr 2024)
  4. Busting Myths about Lung cancer, Lung Cancer Network Malaysia Public Forum, Lung Cancer Network Malaysia (National) (18 Nov 2023 - 18 Nov 2023)
  5. Challenges in Managing SCLC, Annual Scientific Congress of Malaysian Oncological Society (ASCOMOS 2023), MALAYSIAN ONCOLOGICAL SOCIETY (National) (06 Oct 2023 - 08 Oct 2023)
  6. Evolution of Treatment Landscape in 1L ALK+ NSCLC, 10th ANNIVERSARY IKN ONCOLOGY SCIENTIFIC CONFERENCE: STEERING CANCER CARE TOWARDS GREATER HEIGHTS, Institut Kanser Negara (National) (19 Sep 2023 - 20 Sep 2023)
  7. Tailoring Treatment and Biomarker, Masterclass in Systemic Cancer Therapy, University of Malaya (National) (15 Jul 2023 - 16 Jul 2023)
  8. Breaking Frontiers In The Management Of Advanced NSCLC With Pembrolizumab, Breaking Frontiers In The Management Of Advanced NSCLC With Pembrolizumab, MSD (National) (28 Jun 2023 - 28 Jun 2023)
  9. Addressing resistance to immune checkpoint inhibitors, Annual Scientific Congress of Malaysian Oncological Society (ASCOMOS) 2022, Malaysian Oncological Society (National) (04 Nov 2022 - 06 Nov 2022)
  10. Management of ER+HER2-mBC through Clinical & Real-World Evidence, CME, Pfizer Oncology (University) (19 May 2022 - 19 May 2022)
  11. Management of Metastatic Renal Cell Carcinoma, Advanced Urology Course : Urological Oncology, Malaysian Urological Association (National) (19 Feb 2022 - 19 Feb 2022)
  12. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA., Best of ASCO Sri Lanka, 2021, Sri Lanka College of Oncologists (International) (18 Dec 2021 - 19 Dec 2021)
  13. Tumour Agnostic Therapies for Targetable Mutations, Annual Scientific Congress of Malaysian Oncological Society 2021, Malaysian Oncological Society (National) (29 Oct 2021 - 31 Oct 2021)
  14. Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma, Best of ASCO, Malaysia 2021, Malaysian Oncological Society (International) (31 Jul 2021 - 01 Aug 2021)
INVITED SPEAKER
  1. Advancing Targeted Treatment in ALK-Positive Lung Cancer with Brain Metastasis, Cancer ECHO UM, University of Malaya (National) (25 Sep 2024 - 25 Sep 2024)
  2. Dealing with The Big C: Malignancy and Rheumatic Conditions, Multidisciplinary Interactive Symposium in Immunology (MISI) 2024, AbbVie (International) (18 May 2024 - 19 May 2024)
  3. Understanding Comprehensive Molecular Profiling and its Clinical Impact, Caris Life Sciences Back to Basics Webinar, Caris Life Sciences (National) (23 Mar 2024 - 23 Mar 2024)
  4. Role of CCRT for Unresectable Stage 3 Patient with Curative Intent, Evolving Treatment Landscape in Early-stage Lung Cancer Management, Astra Zeneca (National) (07 Mar 2024 - 07 Mar 2024)
  5. Challenges in the management of nasopharyngeal cancer Malaysian perspective, 12th NPC Research Day (2024), Faculty of Dentisry, University of Malaya (International) (07 Mar 2024 - 07 Mar 2024)
  6. Pushing the Boundaries in Revitalising EGFR+ NSCLC Treatment Landscape., Pfizer Round Table Discussion, Pfizer (National) (21 Feb 2024 - 21 Feb 2024)
  7. Navigating Pathway in Optimize Patient Outcome in 1L ALK+ NSCLC, TAKEDA Lung Expert Round Table Discussion, Takeda (International) (19 Jan 2024 - 19 Jan 2024)
  8. Contouring for High Grade Glioma, UM-Varian Contouring Masterclass, Varian (National) (08 Dec 2023 - 08 Dec 2023)
  9. OAR Contouring and Case Discussion, Advanced Radiotherapy Technique in Lung Cancer Management, UMMC (National) (03 Nov 2023 - 03 Nov 2023)
  10. Update in the treatment of lung cancer and interaction with radiotherapy, Advanced Radiotherapy Technique in Lung Cancer Management, UMMC (National) (03 Nov 2023 - 03 Nov 2023)
  11. Revolutionising Patient Quality of Life: Can we eradicate CINV soon, Leading Cancer Care Summit (LCCS) 2023, Juniper Biologics (International) (15 Sep 2023 - 15 Sep 2023)
  12. Clinical Oncology: How to get into training and make the most of it?, UM Cancer Echo, UMMC (National) (08 Mar 2023 - 08 Mar 2023)
  13. How to get into training make the most of it!, UM Cancer Echo, University of Malaya, Clinical Oncology Department (National) (08 Mar 2023 - 08 Mar 2023)
  14. Tailoring treatment in special situations, Masterclass in Systemic Cancer Therapy (MSCT) 2022, University of Malaya Medical Centre (National) (30 Jul 2022 - 31 Jul 2022)
  15. KRAS G12C Mutation Case Presentation, Asian Thoracic Oncology Research Group (ATORG) Molecular Tumour Board, ATORG (International) (29 Jun 2022 - 29 Jun 2022)
  16. Cancer Screening, World Cancer Day 2022, University of Malaya Medical Centre (National) (19 Feb 2022 - 19 Feb 2022)
  17. Avoiding Immune Destruction, Hallmarks of Cancer, University of Malaya (National) (09 Oct 2021 - 10 Oct 2021)
  18. Tailoring treatment in special situations, Masterclass of Systemic Cancer Therapy 2021, University of Malaya (National) (04 Sep 2021 - 12 Sep 2021)
ORAL PRESENTER
  1. Outcome and Transcriptomic Features of Dual EGFR and MET blockade in NSCLC, Annual Scientific Congress of Malaysian Oncological Society 2024, Malaysian Oncological Society (National) (11 Oct 2024 - 13 Oct 2024)
  2. A home-grown clinical oncology training program to address the shortage of oncologists in Malaysia, ESTRO Meets Asia 2024, European Society for Radiotherapy and Oncology (ESTRO) (International) (24 Aug 2024 - 24 Aug 2024)
  3. Maintaining a National Essential Medicine List For Cancer: Where Do We Stand?, Annual Scientific Congress of Malaysian Oncological Society 2021, Malaysian Oncological Society (National) (29 Oct 2021 - 31 Oct 2021)
  4. Limitation of tyrosine kinase inhibitors (TKIs) as second-line treatment in epidermal growth factor receptor (EGFR) activating mutation advanced non-small cell lung cancer (NSCLC) : A retrospective cohort study, Asia Pacific Lung Cancer Conference, International Association for the Study of Lung Cancer (IASLC) (International) (06 Nov 2014 - 08 Nov 2014)
POSTER PRESENTER
  1. Outcome and Transcriptomic Features of Dual EGFR and MET Blockade in NSCLC, World Congress on Lung Cancer 2024, International Association for the Study of Lung Cancer (IASLC) (International) (07 Sep 2024 - 10 Sep 2024)
  2. Implementation of hippocampal sparing wholebrain radiotherapy in a resource-limited setting., ASCO Breakthrough 2024, American Society of Clinical Oncology (International) (08 Aug 2024 - 10 Aug 2024)
  3. Navigating a challenging case of MET amplified gastric cancer via the Molecular Tumor Board, ESMO Asia 2023, European Society of Medical Oncology (International) (01 Dec 2023 - 03 Dec 2023)
  4. Transcriptomics-enabled Molecular Tumor Board at a Tertiary Cancer Centre in Singapore, Singhealth Duke-NUS Scientific Congress 2023, Singhealth (International) (22 Sep 2023 - 23 Sep 2023)
  5. Creating a cancer advocacy program in Indonesia., ASCO Breakthrough 2023, American Society of Clinical Oncology (International) (03 Aug 2023 - 05 Aug 2023)
  6. Circulating tumour DNA (ctDNA) burden quantified through low-pass whole genome sequencing as an early pharmacodynamic biomarker of therapeutic response in patients enrolled on phase 1 trials., ASCO Breakthrough 2023, American Society of Clinical Oncology (International) (03 Aug 2023 - 05 Aug 2023)
  7. Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand? , ESMO Asia 2022, European Society of Medical Oncology (International) (02 Dec 2022 - 04 Dec 2022)
  8. Serous ovarian cancer treated with palbociclib and letrozole , ESMO Asia 2019, European Society of Medical Oncology (International) (22 Nov 2019 - 24 Nov 2019)
  9. Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study, JSMO Annual Meeting 2019, Japanese Society of Medical Oncology (International) (18 Jul 2019 - 20 Jul 2019)
  10. Concurrent nivolumab and radiotherapy in treatment of lung squamous cell carcinoma, ESMO Asia 2018, European Society of Medical Oncology (International) (23 Nov 2018 - 25 Nov 2018)
  11. Incidence Of Febrile Neutropenia With Docetaxel In Breast Cancer Patients, Malaysia-Singapore Congress of Medicine 2018, Malaysian Oncological Society (International) (27 Jul 2018 - 29 Jul 2018)
  12. A rare case of metastatic basal cell carcinoma, ASCOMOS 2017, Malaysian Oncological Society (National) (08 Dec 2017 - 10 Dec 2017)
  13. Two unusual cases of external auditory meatus involvement in NPC , ESMO Asia 2017, European Society of Medical Oncology (International) (17 Nov 2017 - 19 Nov 2017)
  14. Treatment of heavily pre-treated metastatic breast cancer with eribulin: First local experience in Sabah, Sabah Medical Research and Scientific Conference 2015, CRC, Hospital Wanita Dan Kanak Kanak Sabah (National) (15 Oct 2015 - 16 Oct 2015)
  15. Nasopharyngeal carcinoma with paraneoplastic leukemoid reaction: A case report, Sabah Medical Research and Scientific Conference 2014, CRC, Hospital Queen Elizabeth (National) (03 Nov 2014 - 04 Nov 2014)

ACADEMIC/PROF. SERVICES

Evaluation
  1. (2024) Reviewer for Npj Precision Oncology, International, (Reviewer)
  2. (2024) Reviewer for Medical Journal of Malaysia, National, (Reviewer)
  3. (2023) Reviewer for Journal of Health and Translational Medicine (Jummec), International, (Reviewer)
  4. (2023) Reviewer for Medical Journal of Malaysia (Mjm), International, (Reviewer)
  5. (2023) Internal Examiner : Master of Clinical Oncology Part 1 - Radiobiology, University, (Internal Examiner)
  6. (2023) Internal Examiner : Master of Clinical Oncology Part 2, University, (Internal Examiner)
  7. (2023) Abstract Reviewer for The 34th Annual Scientific Congress of Malaysian Oncological Society 2023, National, (Reviewer)
  8. (2023) Reviewer for Medical Journal of Malaysia (Mjm), International, (Reviewer)
  9. (2022) Master of Clinical Oncology (Part 1 Examination), University, (Internal Examiner)
  10. (2022) Internal Examiner - Master of Clinical Oncology Final Examination May 2022, University, (Internal Examiner)
  11. (2022) Phd Proposal: Characterisation of Graphite Detector for Medical Dosimetry by Anis Suhana Binti Ahmad Sabri, University, (Internal Assessor)
  12. (2022) Internal Examiner: Required Summative Assessment 1, Peringkat 2, MBBS, Sesi 2021/2022 - Osce 1, University, (Internal Examiner)
Contribution to external organisation
  1. (2024) Expert for The Pan-Asia Adapted Esmo Clinical Practice Guidelines On Oncogene-Addicted Metastatic Non- Small-Cell Lung Cancer, International, (Technical Advisor)
  2. (2024) Atorg Perioperative Treatment Consensus in Lung Cancer, International, (Resource Person)
  3. (2024) External Reviewer of Sunway Medical Centre Independent Research Ethics Committee, National, (Auditor)

SUPERVISION

SOCIAL RESPONSIBILITY ACTIVITIES

  • Mos Cancer Fun Run 2024, (21 Jan 2024 - 21 Jan 2024) (National)
  • The Blue Cap Relay Run for Prostate Cancer 2023, (24 Sep 2023 - 24 Sep 2023) (University)